No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections.
A previous study at our institution revealed 98% of methicillin-resistant Staphylococcus aureus (MRSA) isolates were susceptible to clindamycin; however, beta-lactams were then the predominant empiric treatment. This follow-up chart review study examined subsequent staphylococcal skin and soft tissue infection treatment and susceptibility patterns over a 2-year period. Of 296 S. aureus skin and soft tissue infections, 73% were MRSA, of which 87% were community-associated-MRSA; MRSA infections peaked in warm summer months. Despite a significant increase in empiric clindamycin use, 97% of community-associated-MRSA isolates retained susceptibility to clindamycin.
Szczesiul
Jillian M
JM
Department of Pharmacy, The Johns Hopkins Hospital, The Johns Hopkins University, Baltimore, MD, USA. jilliansz13@aol.com
Shermock
Kenneth M
KM
Murtaza
Umbreen Idrees
UI
Siberry
George K
GK
D000046:Academic Medical Centers; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015142:Baltimore / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D002981:Clindamycin / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D008712:Methicillin / Q000627:therapeutic use; D016106:Methicillin Resistance / Q000187:drug effects*; D012307:Risk Factors; D012621:Seasons; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000453:epidemiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D008712:Methicillin